522 related articles for article (PubMed ID: 16919506)
1. Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study.
Urinary Incontinence Treatment Network (UITN)
Contemp Clin Trials; 2007 Jan; 28(1):48-58. PubMed ID: 16919506
[TBL] [Abstract][Full Text] [Related]
2. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
3. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
4. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women.
Burgio KL; Goode PS; Richter HE; Markland AD; Johnson TM; Redden DT
J Urol; 2010 Aug; 184(2):598-603. PubMed ID: 20639023
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
Kelleher CJ; Reese PR; Pleil AM; Okano GJ
Am J Manag Care; 2002 Dec; 8(19 Suppl):S608-15. PubMed ID: 12516955
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
7. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
[TBL] [Abstract][Full Text] [Related]
9. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
Kelleher CJ; Kreder KJ; Pleil AM; Burgess SM; Reese PR
Am J Manag Care; 2002 Dec; 8(19 Suppl):S616-30. PubMed ID: 12516956
[TBL] [Abstract][Full Text] [Related]
10. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
Takei M; Homma Y;
Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
[TBL] [Abstract][Full Text] [Related]
14. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.
Burgio KL; Kraus SR; Menefee S; Borello-France D; Corton M; Johnson HW; Mallett V; Norton P; FitzGerald MP; Dandreo KJ; Richter HE; Rozanski T; Albo M; Zyczynski HM; Lemack GE; Chai TC; Khandwala S; Baker J; Brubaker L; Stoddard AM; Goode PS; Nielsen-Omeis B; Nager CW; Kenton K; Tennstedt SL; Kusek JW; Chang TD; Nyberg LM; Steers W;
Ann Intern Med; 2008 Aug; 149(3):161-9. PubMed ID: 18678843
[TBL] [Abstract][Full Text] [Related]
15. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
Choo MS; Doo CK; Lee KS
Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
17. Impact of a health education intervention in overactive bladder patients.
Herschorn S; Becker D; Miller E; Thompson M; Forte L
Can J Urol; 2004 Dec; 11(6):2430-7. PubMed ID: 15636668
[TBL] [Abstract][Full Text] [Related]
18. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Wein AJ
J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
[No Abstract] [Full Text] [Related]
19. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
Wein AJ; Khullar V; Wang JT; Guan Z
BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
Roberts RG; Garely AD; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
